source
- Artiva to quit autoimmune cell therapy work, cut staff after patient deathsThe disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.BioPharma Dive · 19d ago↗ source
- After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforceArtiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include diss…BioSpace · 19d ago↗ source
- Amgen’s Imdelltra plus AstraZeneca’s Imfinzi cuts death risk by ~60% in extensive-stage small cell lung cancerAmgen presented Phase 3 data at ESMO 2026 showing that its bispecific T‑cell engager Imdelltra, when added to AstraZeneca’s checkpoint inhibitor Imfinzi, significantly reduced mortality in extensiv…